ATE429222T1 - Medikamente zur behandlung oder prävention fibrotischer krankheiten - Google Patents

Medikamente zur behandlung oder prävention fibrotischer krankheiten

Info

Publication number
ATE429222T1
ATE429222T1 AT05823903T AT05823903T ATE429222T1 AT E429222 T1 ATE429222 T1 AT E429222T1 AT 05823903 T AT05823903 T AT 05823903T AT 05823903 T AT05823903 T AT 05823903T AT E429222 T1 ATE429222 T1 AT E429222T1
Authority
AT
Austria
Prior art keywords
medications
prevention
treatment
fibrotic diseases
fibrotic
Prior art date
Application number
AT05823903T
Other languages
English (en)
Inventor
John Park
Nveed Chaudhary
Gerald Roth
Armin Heckel
Thorsten Lehmann-Lintz
Joerg Kley
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE429222T1 publication Critical patent/ATE429222T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05823903T 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten ATE429222T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030769 2004-12-24
PCT/EP2005/057013 WO2006067175A1 (en) 2004-12-24 2005-12-21 Medicaments for the treatment or prevention of fibrotic diseases

Publications (1)

Publication Number Publication Date
ATE429222T1 true ATE429222T1 (de) 2009-05-15

Family

ID=35717457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823903T ATE429222T1 (de) 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten

Country Status (26)

Country Link
US (3) US20060148883A1 (de)
EP (1) EP1835907B1 (de)
JP (1) JP5748386B2 (de)
KR (1) KR20070092305A (de)
CN (1) CN101087604B (de)
AR (1) AR052439A1 (de)
AT (1) ATE429222T1 (de)
AU (1) AU2005318136B2 (de)
BR (1) BRPI0519351A2 (de)
CA (1) CA2591089C (de)
DE (1) DE602005014145D1 (de)
DK (1) DK1835907T3 (de)
EA (1) EA200701181A1 (de)
ES (1) ES2326277T3 (de)
HR (1) HRP20090312T1 (de)
IL (1) IL184124A0 (de)
MX (1) MX2007007676A (de)
NO (1) NO20073830L (de)
PE (1) PE20061155A1 (de)
PL (1) PL1835907T3 (de)
PT (1) PT1835907E (de)
RS (1) RS50833B (de)
SI (1) SI1835907T1 (de)
TW (1) TW200637544A (de)
WO (1) WO2006067175A1 (de)
ZA (1) ZA200703600B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514468B2 (en) * 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) * 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
JP5174802B2 (ja) * 2007-03-02 2013-04-03 三井化学株式会社 不織布積層体
JP5524852B2 (ja) * 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
US20090131359A1 (en) * 2007-11-19 2009-05-21 Atamas Sergei P Antifibrotic therapy
EP2238108B1 (de) * 2008-01-25 2012-08-29 Boehringer Ingelheim International GmbH Salzformen eines 6-fluor-1,2-dihydro-2-oxo-3h-indol-3-ylidenderivats, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
JP2012503619A (ja) * 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
WO2012103520A1 (en) * 2011-01-28 2012-08-02 Board Of Regents Of The University Of Nebraska Methods and compositions for modulating cyclophilin d
US10450295B2 (en) 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59906030D1 (de) * 1998-09-25 2003-07-24 Boehringer Ingelheim Pharma Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7169936B2 (en) * 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
PE20040701A1 (es) * 2002-07-23 2004-11-30 Boehringer Ingelheim Pharma Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos

Also Published As

Publication number Publication date
AU2005318136B2 (en) 2012-02-09
RS50833B (sr) 2010-08-31
JP5748386B2 (ja) 2015-07-15
US20140128409A1 (en) 2014-05-08
US20060148883A1 (en) 2006-07-06
EA200701181A1 (ru) 2008-02-28
WO2006067175A1 (en) 2006-06-29
US20120004202A1 (en) 2012-01-05
PL1835907T3 (pl) 2009-08-31
CA2591089A1 (en) 2006-06-29
DK1835907T3 (da) 2009-08-03
KR20070092305A (ko) 2007-09-12
PE20061155A1 (es) 2006-12-16
NO20073830L (no) 2007-07-23
HRP20090312T1 (hr) 2009-07-31
AR052439A1 (es) 2007-03-21
BRPI0519351A2 (pt) 2009-01-20
PT1835907E (pt) 2009-06-16
DE602005014145D1 (de) 2009-06-04
EP1835907B1 (de) 2009-04-22
ES2326277T3 (es) 2009-10-06
TW200637544A (en) 2006-11-01
ZA200703600B (en) 2008-07-30
CN101087604B (zh) 2010-10-13
EP1835907A1 (de) 2007-09-26
IL184124A0 (en) 2007-10-31
JP2008525374A (ja) 2008-07-17
SI1835907T1 (sl) 2009-10-31
AU2005318136A1 (en) 2006-06-29
CN101087604A (zh) 2007-12-12
MX2007007676A (es) 2007-08-14
CA2591089C (en) 2014-02-11

Similar Documents

Publication Publication Date Title
SI2878297T1 (sl) Zdravila za zdravljenje ali preprečevanje fibroznih bolezni
EP1759710A4 (de) Mittel zur behandlung oder prävention von arthritis
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
DE602006010364D1 (de) Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen
DE602005014624D1 (de) Verbindungen zur behandlung von krankheiten
DE602005023842D1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
GB0407710D0 (en) Treatment of diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1835907

Country of ref document: EP